

pegcetacoplan (Empaveli™)

Policy # 00768

Original Effective Date: 12/13/2021

Current Effective Date: 06/01/2026

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Investigational or experimental services are not covered. This includes any drug, device, procedure, or service provided under the investigational arm of a clinical trial or clinical study. These services are excluded from coverage under benefits.

Note: pegcetacoplan (Syfovre™)† is addressed separately in medical policy 00850.

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member’s contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Paroxysmal Nocturnal Hemoglobinuria

Based on review of available data, the Company may consider the use of pegcetacoplan (Empaveli™)† for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) to be **eligible for coverage.****

Patient Selection Criteria

Coverage eligibility for pegcetacoplan (Empaveli) will be considered when the following criteria are met:

I. Initial Therapy

- A. Patient has received vaccination against meningococcal infections within 2 years prior to, or at the time of initiating the requested drug; AND
- B. If the drug is initiated less than 2 weeks after meningococcal vaccination, patient will receive prophylactic antibiotics until 2 weeks after vaccination; AND
- C. Patient is 18 years of age or older; AND
- D. Documentation is provided of peripheral blood high sensitivity flow cytometry results showing a granulocyte or monocyte clone size of greater than or equal to 5%; AND
- E. Patient meets ONE of the following (i OR ii):
 - i. Patient has at least ONE of the following significant disease manifestations caused by hemolysis (a, b, c, d, OR e):
 - a) Documented history of a major adverse vascular event (MAVE) from thromboembolism; OR
 - b) Presence of organ damage secondary to chronic hemolysis (e.g., worsening renal insufficiency); OR

Policy # 00768

Original Effective Date: 12/13/2021

Current Effective Date: 06/01/2026

- c) Patient is transfusion-dependent as evidenced by 2 or more transfusions in the 12 months prior to initiation of treatment; OR
- d) Patient has a high lactate dehydrogenase (LDH) activity (defined as greater than or equal to 1.5 x the upper limit of normal) with clinical symptoms (e.g., severe fatigue, dyspnea, jaundice, abdominal or chest pain, discolored urine, dysphagia, pulmonary hypertension); OR
- e) Patient has symptomatic anemia with a hemoglobin less than the lower limit of normal; OR
- ii. Patient has been previously receiving eculizumab (Soliris®)†, ravulizumab (Ultomiris™)†, iptacopan (Fabhalta®)†, or crovalimab-akkz (PiaSky®)† for the treatment of PNH and is switching to pegcetacoplan (Empaveli); AND
*(Note: These specific patient selection criteria are additional Company requirements for coverage eligibility and will be denied as not medically necessary** if not met.)*
- F. For a patient transitioning to pegcetacoplan (Empaveli) from eculizumab (Soliris), ravulizumab (Ultomiris), iptacopan (Fabhalta), crovalumab-akkz (PiaSky), or danicopan (Voydeya™)†; the prescriber attests that these medications will be discontinued within 4 weeks after starting Empaveli.

II. Continuation Therapy

- A. Patient has received an initial authorization for Empaveli; AND
- B. Patient has experienced improvement on therapy as evidenced by at least ONE of the following (i, ii, OR iii):
 - i. Decreased serum LDH compared to pretreatment baseline; OR
 - ii. Decreased need for blood transfusion compared to pretreatment baseline; OR
 - iii. Stabilization of hemoglobin; AND
*(Note: These specific patient selection criteria are additional Company requirements for coverage eligibility and will be denied as not medically necessary** if not met.)*
- C. Empaveli will not be used in combination with Soliris, Ultomiris, Fabhalta, PiaSky, or Voydeya.
*(Note: This specific patient selection criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met.)*

Complement 3 Glomerulopathy (C3G) and Primary Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN)

Based on review of available data, the Company may consider the use of pegcetacoplan (Empaveli) for the treatment of complement 3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) to be **eligible for coverage.****

Patient Selection Criteria

Coverage eligibility for pegcetacoplan (Empaveli) will be considered when the following criteria are met:

I. Initial Therapy

- A. Patient has received vaccination against meningococcal infections within 2 years prior to, or at the time of initiating the requested drug; AND

Policy # 00768

Original Effective Date: 12/13/2021

Current Effective Date: 06/01/2026

- B. If the drug is initiated less than 2 weeks after meningococcal vaccination, patient will receive prophylactic antibiotics until 2 weeks after vaccination; AND
- C. Patient is 12 years of age or older; AND
- D. Patient has a diagnosis of complement 3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) confirmed by kidney biopsy; AND
*(Note: The requirement that diagnosis be confirmed by kidney biopsy is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met.)*
- E. Infection-related or post-infectious glomerulonephropathy has been ruled out; AND
*(Note: This specific patient selection criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met.)*
- F. Patient has a urine protein-to-creatinine ratio (UPCR) greater than or equal to 1 g/g AND an estimated glomerular filtration rate (eGFR) greater than or equal to 30 mL/min/1.73 m²; AND
- G. Patient has been receiving the maximally tolerated dose of an angiotensin converting enzyme inhibitor (ACEi) (e.g., lisinopril, enalapril, benazepril, captopril, fosinopril, moexipril, perindopril, quinapril, ramipril, trandolapril) or angiotensin receptor blocker (ARB) (e.g., candesartan, irbesartan, losartan, olmesartan, telmisartan, valsartan) for greater than 90 days; AND
*(Note: This specific patient selection criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met.)*
- H. Empaveli will not be used in combination with (iptacopan) Fabhalta.
*(Note: This specific patient selection criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met.)*

II. Continuation therapy

- A. Patient has received an initial authorization for Empaveli for C3G or IC-MPGN; AND
- B. According to the prescribing physician, patient is continuing to derive benefit from Empaveli. Examples of treatment benefits include reduction in urine protein-to-creatinine ratio from baseline or reduction in proteinuria from baseline; AND
*(Note: This specific patient selection criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met.)*
- C. Empaveli will not be used in combination with Fabhalta.
*(Note: This specific patient selection criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met.)*

When Services Are Considered Not Medically Necessary

Based on review of available data, the Company considers the use of pegcetacoplan (Empaveli) for PNH when the patient does not have a manifestation of significant disease or has not been previously receiving eculizumab (Soliris), ravulizumab (Ultomiris), iptacopan (Fabhalta), crovalaumab-akkz (Piasky), or danicopan (Voydeya) for PNH to be **not medically necessary.****

pegcetacoplan (Empaveli™)

Policy # 00768

Original Effective Date: 12/13/2021

Current Effective Date: 06/01/2026

Based on review of available data, the Company considers the use of pegcetacoplan (Empaveli) for C3G or IC-MPGN when the patient's diagnosis has not been confirmed by kidney biopsy, infection-related or post-infectious glomerulonephropathy has not been ruled out, or the patient has not been receiving the maximally tolerated dose of an ACEi or ARB for greater than 90 days to be **not medically necessary**.**

Based on review of available data, the Company considers the use of pegcetacoplan (Empaveli) in combination with another disease-modifying treatment for the patient's condition to be **not medically necessary**.**

Based on review of available data, the Company considers the continued use of pegcetacoplan (Empaveli) for PNH, C3G or IC-MPGN when the patient has not demonstrated improvement while on therapy to be **not medically necessary**.**

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers the use of pegcetacoplan (Empaveli) when the patient selection criteria are not met (except those noted to be **not medically necessary****) to be **investigational**.*

Background/Overview

Empaveli is a C3 complement inhibitor indicated for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adults and complement 3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older. It binds to complement protein C3 and acts proximally in the complement cascade to control both C3b-mediated extravascular hemolysis and terminal complement-mediated intravascular hemolysis. For all indications in adults, it should be dosed as 1,080 mg by subcutaneous infusion twice weekly via a commercially available infusion pump with a reservoir of at least 20 mL or via a single-use, disposable on body injector. For patients 12 to 18 years of age, the dose is based on weight and administered twice weekly. Other treatments available for PNH include the C5 complement inhibitors Soliris, Ultomiris, and PiaSky; the Factor B inhibitor Fabhalta; and the Factor D inhibitor Voydeya. It should be noted that Empaveli was demonstrated to be superior to Soliris in clinical trials and also has the advantage of easier administration. The only other treatment approved for C3G at this time is Fabhalta. Empaveli is the first drug FDA approved for IC-MPGN.

Paroxysmal Nocturnal Hemoglobinuria (PNH)

PNH is an acquired hematopoietic stem cell disorder associated with an acquired somatic mutation of the phosphatidylinositol glycan class A (PIGA) gene. Mutations disrupt the first step in glycosylphosphatidylinositol (GPI) synthesis, which causes an absence of the GPI anchor and a deficiency of GPI proteins. The absence of GPI proteins on erythrocytes makes them susceptible to attack by complement and intravascular hemolysis. Intravascular hemolysis associated with PNH leads to release of free hemoglobin, leading to anemia, hemoglobinuria, thrombosis, dysphagia,

abdominal pain, pulmonary hypertension, renal impairment, and erectile dysfunction. The prevalence of PNH is estimated to be between 0.5-1.5 per million people in the general population, with an approximately equal male to female distribution. Although PNH can affect any age group, the median age at diagnosis is during the fourth decade of life. The primary clinical finding is hemolysis of red blood cells by complement, which leads to hemoglobinuria that is most prominent in the morning. Those with PNH are also susceptible to repeated, potentially life-threatening thromboses. Underlying bone marrow dysfunction may also be present and those who are severely affected may have pancytopenia. Many patients also have acquired aplastic anemia. Although less common, some patients have concomitant myelodysplasia. For unknown reasons, PNH may rarely develop into acute leukemia.

Signs and symptoms of PNH may vary, with some patients exhibiting mild and stable disease for many years while other patients have severe symptoms that rapidly progress to life-threatening. However, chronic hemolysis is central to all of the symptoms and physical findings associated with PNH. Fatigue, rapid heartbeat, headaches, and chest pain and difficulty breathing while exercising can result from mild hemolysis. With severe hemolysis, disabling fatigue, dysphagia, and painful contractions of the abdomen and esophagus may occur. It is estimated that 15-30% of patients with PNH develop blood clots, particularly venous thrombosis. Diagnosis of PNH is suspected in those with unexplained hemoglobinuria or abnormally high serum lactate dehydrogenase (LDH) levels. However, flow cytometry is the main diagnostic test for the identification of PNH cells.

There are no formal guidelines for treatment of PNH. However, there is an expert opinion for management of PNH published in a journal supported by the American Society of Hematology. Diagnosis of PNH is straightforward based on flow cytometry and specific treatment is recommended based on classification by the PNH interest group. Soliris is recommended for patients with classic PNH characterized by >50% of GPI-AP-deficient PMNs as well as patients with PNH in the setting of another bone marrow failure syndrome with large PNH clones. No specific PNH therapy is recommended for patients with subclinical PNH with no clinical or biochemical evidence of intravascular hemolysis. This review was published before the approval of Ultomiris, Empaveli, Fabhalta, PiaSky, and Voydeya.

Complement 3 Glomerulopathy (C3G) and Primary Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN)

C3G and IC-MPGN are rare glomerular diseases that share a membranoproliferative pattern of injury but differ in pathogenesis: C3G is driven by dysregulation of the alternative complement pathway with C3-dominant glomerular deposition, whereas primary IC-MPGN is mediated by immune-complex deposition with associated complement activation. Damage to the glomeruli impairs blood filtration, leading to proteinuria, toxin accumulation, and progressive kidney injury, with clinical presentation varying widely; diagnosis relies on kidney biopsy with immunofluorescence. Historically, treatment—particularly for C3G—has been stratified by disease severity and focused on supportive care and immunosuppression with mycophenolate mofetil and/or glucocorticoids, with eculizumab considered in select refractory cases based on clinical practice guidelines published prior to the approval of targeted complement inhibitors. Although Fabhalta and Empaveli are now FDA-approved therapies for C3G (and Empaveli for primary IC-MPGN), their optimal sequencing and long-term placement in therapy continue to evolve.

pegcetacoplan (Empaveli™)

Policy # 00768

Original Effective Date: 12/13/2021

Current Effective Date: 06/01/2026

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

Empaveli was approved in May 2021 for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria. In July 2025, it received the additional indication to reduce proteinuria in patients 12 years and older with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis.

Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to regulations, other plan medical policies, and accredited national guidelines.

Paroxysmal Nocturnal Hemoglobinuria

The efficacy and safety of Empaveli in patients with PNH were assessed in a randomized, open-label, active comparator-controlled, 16-week, study. The study enrolled patients with PNH who had been treated with a stable dose of eculizumab for at least the previous 3 months and with Hb levels less than 10.5 g/dL.

Eligible patients entered a 4-week run-in period during which they received Empaveli 1,080 mg subcutaneously twice weekly in addition to their current dose of eculizumab. Patients were then randomized in a 1:1 ratio to receive either 1,080 mg of Empaveli twice weekly or their current dose of eculizumab through the duration of the 16-week randomized controlled period. If required, the dose of Empaveli could be adjusted to 1,080 mg every 3 days. Empaveli was administered as a subcutaneous infusion over 20 to 40 minutes. Following completion of the randomized controlled period, all patients entered a 32-week open-label period and received monotherapy with Empaveli. All patients who completed the 48-week period were eligible to enroll in a separate long-term extension study.

A total of 80 patients were randomized to receive treatment, 41 to Empaveli and 39 to eculizumab. The efficacy measure of Empaveli was based on change from baseline to Week 16 in hemoglobin level. Baseline was defined as the average of measurements recorded prior to taking the first dose of Empaveli. At the end of Week 16, Empaveli was found to be superior to eculizumab in the change in hemoglobin level ($p < 0.0001$). The adjusted mean change from baseline in hemoglobin level was 2.37 g/dL in the Empaveli group versus -1.47 g/dL in the eculizumab group, demonstrating an adjusted mean increase of 3.84 g/dL with Empaveli compared to eculizumab at Week 16 (95% CI, 2.33-5.34).

An additional study (the PRINCE study) was conducted in patients with PNH who were treatment-naïve to complement inhibitors. This was a phase III, multicenter, randomized, open-label, controlled treatment evaluating the efficacy and safety of Empaveli compared with supportive care (e.g., blood transfusions, anticoagulants, corticosteroids, supplements) in 53 complement-inhibitor-naïve patients with PNH. Patients were randomized 2:1 to receive Empaveli twice weekly or control treatment through Week 26.

pegcetacoplan (Empaveli™)

Policy # 00768

Original Effective Date: 12/13/2021

Current Effective Date: 06/01/2026

Empaveli was superior to control treatment in both co-primary endpoints of hemoglobin stabilization (i.e. avoidance of a > 1 g/dL decrease in hemoglobin level in the absence of blood transfusions) and change in LDH level from baseline to Week 26. Hemoglobin stabilization was achieved by 85.7% ($n = 30$) of patients treated with Empaveli and 0 of control arm patients through Week 26 ($p < 0.0001$). Empaveli-treated patients demonstrated superior reductions in mean LDH levels from baseline to Week 26 compared to control arm patients (least-squares mean change from baseline: Empaveli, -18750.5 U/L; control, -400.1 U/L; $p < 0.0001$).

Complement 3 Glomerulopathy (C3G) or Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

The efficacy of Empaveli in reducing proteinuria in adult and pediatric patients aged 12 years and older with native kidney C3G, native kidney IC-MPGN, or recurrent C3G following kidney transplant was demonstrated in Study APL2-C3G-310. Safety and effectiveness of Empaveli in patients with recurrent IC-MPGN following kidney transplant have not been established.

APL2-C3G-310 is a randomized, double-blind, placebo-controlled study that included 124 adult and pediatric patients aged 12 years and older and weighing at least 30 kg with biopsy-proven, native kidney or post-transplant recurrent C3G, or native kidney primary IC-MPGN, $eGFR \geq 30$ mL/min/1.73 m², proteinuria ≥ 1 g/day, and urine protein-to-creatinine ratio (UPCR) ≥ 1 g/g. For at least 12 weeks before randomization and throughout the 26-week placebo-controlled period, patients were required to be on stable and optimized doses of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and/or sodium-glucose cotransporter-2 inhibitors. Immunosuppressant medication doses (e.g., steroids no higher than 20 mg daily, mycophenolate mofetil, tacrolimus) had to be stable for at least 12 weeks before randomization and throughout the 26-week placebo-controlled period.

Patients were randomized (1:1) to Empaveli or placebo, administered twice weekly as a subcutaneous infusion for 26 weeks. Patients were vaccinated against *Streptococcus pneumoniae*, *Neisseria meningitidis* types A, C, W, Y, and B, and *Haemophilus influenzae* type B (Hib) at least 14 days prior to randomization, unless documented evidence existed that participants received the recommended vaccinations or were non-responders to vaccination.

Approximately 91% of patients were treated with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, 72% with immunosuppressants, 40% with systemic corticosteroids, and 11% with sodium-glucose co-transporter 2 (SGLT2) inhibitors. Use of each of these medications was balanced between the treatment groups.

The primary efficacy endpoint was the log-transformed ratio of UPCR at Week 26 compared to baseline. At Week 26, the geometric mean UPCR ratio relative to baseline was 0.33 (95% CI: 0.25, 0.43) and 1.03 (95% CI: 0.91, 1.16) in the Empaveli and placebo groups, respectively, resulting in a 68% reduction in UPCR from baseline in the Empaveli group compared to placebo ($p < 0.0001$). The treatment effect was consistent across all subgroups including disease type, age, transplant status (C3G), sex, race, baseline disease characteristics, and immunosuppressant use.

pegcetacoplan (Empaveli™)

Policy # 00768

Original Effective Date: 12/13/2021

Current Effective Date: 06/01/2026

During the 26-week placebo-controlled period, 49% of patients in the Empaveli group achieved a composite renal endpoint defined as $\geq 50\%$ reduction in UPCR and stable eGFR ($\leq 15\%$ reduction from baseline) compared with 3% of the patients in the placebo group (odds ratio [95% CI] of 27 [6, 124], $p < 0.0001$). Sixty percent of patients in the Empaveli group achieved a 50% or greater reduction in UPCR from baseline to Week 26 compared with 5% in the placebo arm, and 68% of patients in the Empaveli group had a stable eGFR compared with 59% in the placebo group. Over the first 6 months of treatment, Empaveli reduced the loss of kidney function compared to placebo. The efficacy of Empaveli in pediatric patients 12 years of age and older was similar to adults.

References

1. Empaveli [package insert]. Apellis Pharmaceuticals, Inc. Waltham, MA. Updated July 2025.
2. Empaveli Drug Evaluation. Express Scripts. Updated May 2021.
3. Wong RSM, Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria. *Ther Adv Hematol*. 2022; 13.
4. Empaveli for C3 Glomerulopathy and IC-MPGN Rx Brief. IPD Analytics. Updated September 2025.

Policy History

Original Effective Date: 12/13/2021

Current Effective Date: 06/01/2026

11/04/2021	Medical Policy Committee review
11/10/2021	Medical Policy Implementation Committee approval. New policy.
05/05/2022	Medical Policy Committee review
05/11/2022	Medical Policy Implementation Committee approval. Updated initial criteria to allow for coverage in patients with symptomatic anemia or who have previously received Soliris or Ultomiris for the treatment of PNH.
05/04/2023	Medical Policy Committee review
05/10/2023	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
05/02/2024	Medical Policy Committee review
05/08/2024	Medical Policy Implementation Committee approval. Updated criteria and background information to include new drug, Fabhalta, for treatment of PNH.
05/01/2025	Medical Policy Committee review
05/13/2025	Medical Policy Implementation Committee approval. Updated criteria and background information to include two new drugs for PNH, PiaSky and Voydeya.
05/07/2026	Medical Policy Committee review
05/13/2026	Medical Policy Implementation Committee approval. Updated policy to include criteria and background information for new indication for Complement 3 Glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis (IC- MPGN).

Next Scheduled Review Date: 05/2027

Policy # 00768

Original Effective Date: 12/13/2021

Current Effective Date: 06/01/2026

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 1. Consultation with technology evaluation center(s);
 2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
 3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

pegcetacoplan (EmpaveliTM)

Policy # 00768

Original Effective Date: 12/13/2021

Current Effective Date: 06/01/2026

NOTICE: Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage.

NOTICE: If an authorization for an ongoing course of treatment has been provided to a member and the member changes from one health plan to another health plan (e.g., a member moves from carrier A to Louisiana Blue), Louisiana Blue may honor the previous health plan's authorization for the same service under the same type of in-network benefit for a 90-day transition period. Documentation of the authorization for the ongoing course of treatment from the previous health plan must be provided to us by the member or their provider and the services provided for the course of treatment must otherwise be a covered service under the Louisiana Blue health plan. This provision does not apply to medications covered under the plan's pharmacy benefit.